Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inboxGmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscriptionClick this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
Exclusive Story from MarketBeat
AbbVie Fires Healthy Trend-Following Signal: Is a Rebound Ahead?Written by Thomas Hughes. Date Posted: 4/29/2026. 
Key Points
- AbbVie is amid a trend-following opportunity, underpinned by cash flow and capital return.
- Institutions are accumulating aggressively, limiting downside risk in Q2.
- Analyst trends suggest a fresh all-time high is coming; the only question is how quickly the stock price will rise.
- Special Report: Elon Musk already made me a “wealthy man”
AbbVie's (NYSE: ABBV) share price has been under pressure from rising costs and concerns that its post‑Humira era won’t be as strong. The decline, however, set up a trend‑following buy signal that was triggered after its Q1 earnings results. The results initially disappointed, but a sharp drop at the open prompted heavy buying. The share price rallied off the intraday low, confirming support at a key level and suggesting solid potential for a rebound.
Most investors are reacting to the Iran strikes without understanding the underlying motive driving the decision.
Addison Wiggin, Founder of Grey Swan Investment Fraternity, says there is a hidden reason behind the bombing - and knowing it could change how you position your money right now. Discover the real reason behind the Iran strikes before markets react
AbbVie’s trend‑following signal is based on its long‑term 150‑week exponential moving average (EMA), recent price action and momentum indicators such as MACD and stochastic. The EMA has acted as a long‑running trend line, and the current price action reinforces that relationship. 
The latest candle is a Hammer Doji, a pattern that often signals the end of a downtrend as the market “hammers out” a bottom. Technical indicators show the stock is oversold and bearish momentum is extreme, which sets the stage for a bounce. The likely triggers for that bounce may be straightforward: valuation and the dividend. AbbVie Presents a Value and Yield Opportunity Smart Money Is BuyingAbbVie trades at roughly 14x its current‑year earnings forecast as of late April — about 40% below its long‑term average — which implies significant upside. That potential is supported by an attractive dividend yield of about 3.4% and expectations for distribution growth. Given its ties to Abbott Laboratories (NYSE: ABT), AbbVie has raised its payout every year since the spin‑off. The payout ratio is on the higher side, near 65%, but that level isn’t unusual for a company of this quality. The critical factors are cash flow and the balance sheet, which currently support the dividend and its sustainability. At present, ABBV appears able to maintain its payments and a mid‑single‑digit dividend CAGR for the foreseeable future. Analyst forecasts are consistent with this valuation. The 26 analysts tracked by MarketBeat rate the stock a Moderate Buy, with a roughly 65% buy‑side bias and nearly 30% upside at the consensus target. Activity around price targets in 2026, heading into the Q1 report, included some downgrades but stayed largely clustered around the consensus, suggesting analyst sentiment should remain firm even if a major catalyst from this vector doesn't arrive until later in the year. Institutional interest is even more supportive. Institutions own more than 70% of the stock and have been net buyers over the trailing 12 months. MarketBeat data show institutional buying accelerated in Q1 2025, remained elevated through Q1 2026 and stayed bullish in early Q2, running at better than a $2‑to‑$1 net buying pace. Buying intensified as the price fell, briefly rising to over $4‑to‑$1, which underscores the perceived value opportunity. If this cohort continues to accumulate, ABBV’s bottom is likely in, and a broader rebound may be only a matter of time. AbbVie Puts Patent Cliff in Rear‑View MirrorAbbVie’s Q1 results should ease concerns about the company's patent cliff. Revenue rose 12.4% to $15 billion, driven by strength in Skyrizi and Rinvoq; Humira sales trailed at $668 million. AbbVie also reported studies showing Rinvoq outperformed Humira on the primary endpoint and met secondary objectives, which supports expectations for continued outperformance. By segment, all but Oncology posted growth, led by Neurosciences (+26%) and Immunology (+16.4%). Margins remain a strength. GAAP earnings were pressured by acquired R&D milestones, but adjusted results were stronger. Adjusted EPS of $2.65 rose 7.7% year over year and missed consensus by only a small margin. More importantly, the company raised its full‑year adjusted EPS guidance to better align with market expectations. The likely path forward is continued execution, pipeline progress and potential outperformance in coming quarters. Key catalysts this year include clinical trial readouts — particularly in Oncology — and label or coverage expansions for existing therapies. AbbVie currently has multiple applications in progress to broaden indications for blockbusters such as Rinvoq and Skyrizi. Risks remain, notably competitive pressure on Humira, but that threat lessens with each passing quarter. |
0 Response to "We're excited to have you on board"
Post a Comment